+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Direct Acting Antivirals Market - Global Forecast 2026-2032- Product Image
Direct Acting Antivirals Market - Global Forecast 2026-2032- Product Image
New

Direct Acting Antivirals Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6127542
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The direct acting antivirals market is evolving rapidly, as companies transition from breakthrough innovation to integrated approaches focused on broader access, robust supply, and measurable treatment outcomes across multiple viral infections.

Market Snapshot: Direct Acting Antivirals Market Overview

The direct acting antivirals market continues to demonstrate strong expansion, moving from USD 48.91 billion in 2025 to USD 52.37 billion in 2026. With a compound annual growth rate (CAGR) of 8.13%, projections position the market to achieve USD 84.56 billion by 2032. This progress highlights the increasing reliance on direct acting antivirals (DAAs) as essential platforms within global healthcare delivery, contributing to improved outcomes in viral disease management and reinforcing their significance in clinical execution.

Scope & Segmentation

This report provides a comprehensive breakdown of the market, ensuring senior decision-makers can effectively target growth opportunities and mitigate risk across the following domains:

  • Drug Classes & Mechanisms: Encompasses small-molecule therapies with varied mechanisms, resistance profiles, as well as mono-therapy and combination regimen options to address a broad range of viral pathogens.
  • Regimen Simplicity: Evaluates ease of therapy, focusing on dosing frequency, pill burden, adoption of fixed-dose combinations, and considerations for food-related administration requirements to support adherence.
  • Administration Route & Dosage Form: Distinguishes oral treatments, which facilitate decentralized care models, from injectable and other parenteral solutions intended for specific patient populations or targeted delivery needs.
  • Indications & Therapy Maturity: Covers both well-established and emerging viral targets. Tracks how shifting epidemiology and evolving patterns of disease affect product lifecycle and commercial strategy.
  • Distribution Channels: Highlights delivery models including hospital, institutional, specialty, retail, and public procurement pathways, reflecting diverse strategies for patient access and care delivery.
  • Patient Segments: Examines special populations such as patients with organ impairment, co-infections, or comorbidities, acknowledging the need for tailored regimen choices in these groups.
  • Geographic Regions: Includes key regional landscapes—the Americas, Europe, Middle East, Africa, and Asia-Pacific—addressing reimbursement mechanisms, procurement practices, and pace of regulatory adoption.
  • Technology Adoption: Focuses on advances in precision regimen design, tight control over manufacturing processes, and platforms for real-time evidence generation, all of which enable greater scalability and therapy durability.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Industry priorities have shifted towards efficient translation of molecular targets into comprehensive regimens, with greater weight now placed on access, resilient supply, and demonstrable clinical impact over singular scientific advances.
  • Regimen innovation also includes targeted strategies for resistance management, supporting combination therapies and simpler dosing frameworks to enhance adherence, especially for at-risk or complex patient segments.
  • Successful adoption relies heavily on the operational fit of DAAs within decentralized, outpatient care models, compelling manufacturers to provide extensive evidence of real-world utility and long-term benefits.
  • Market differentiation has intensified, with competition increasingly centered on manufacturing quality, uninterrupted supply, and strategic product lifecycle management, particularly as established therapies encounter competitive generic entry and payer scrutiny.
  • Regional performance and growth are dictated by factors such as procurement strength, reimbursement structure, and the adaptability of DAA integration within local health systems—including resource allocation and public health priorities.
  • Integrated execution that connects scientific innovation, robust commercial operations, and resilient supply strategies is now central to maintaining sustainable competitive positioning within the direct acting antivirals landscape.

Tariff Impact on the Direct Acting Antivirals Market

Recent tariffs imposed in the United States beginning in 2025 have altered the cost dynamics of pharmaceutical inputs. As a response, organizations are adjusting sourcing practices and reinforcing supply chain resilience, impacting areas such as quality assurance, supplier qualification, and contractual relationships. Escalating tariffs heighten the need for dual or diversified sourcing models, which in turn increase operational and regulatory complexity. Companies are responding by strengthening geographic manufacturing diversification and renegotiating supply agreements to maintain continuity and safeguard supply reliability in competitive markets.

Methodology & Data Sources

The analysis in this report is grounded in structured secondary research, drawing from scientific literature, regulatory filings, and corporate reporting, combined with primary interviews across relevant value chain stakeholders. Analytical synthesis ensures insights remain consistent, decision-relevant, and as free from bias as possible.

Why This Report Matters

  • Provides executive leaders with a thorough understanding of the shifting forces that influence access, supply, and strategy in the DAAs sector—enabling proactive risk and opportunity management.
  • Facilitates informed portfolio management and commercialization planning through detailed segmentation, helping pinpoint where operational alignment and clinical clarity deliver strategic value.
  • Delivers concise intelligence on how new tariff policies and evolving regional dynamics can serve as levers for supply resilience, offering actionable support for competitive advantage and resource planning.

Conclusion

The direct acting antivirals market is shaped by integrated strategy across design, evidence, and supply operations. Organizations that unify operational and commercial planning will be best positioned to translate innovation into sustainable benefits and improved patient care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Direct Acting Antivirals Market, by Drug Class
8.1. Ns3/4A Protease Inhibitors
8.1.1. Glecaprevir
8.1.2. Voxilaprevir
8.2. Ns5A Inhibitors
8.2.1. Ledipasvir Sofosbuvir
8.2.2. Velpatasvir Sofosbuvir
8.3. Ns5B Polymerase Inhibitors
8.3.1. Dasabuvir
8.3.2. Sofosbuvir
9. Direct Acting Antivirals Market, by Route Of Administration
9.1. Fixed Dose Combinations
9.1.1. Once Daily Dosing
9.1.2. Twice Daily Dosing
9.2. Single Agent Tablets
9.2.1. Once Daily Dosing
9.2.2. Twice Daily Dosing
10. Direct Acting Antivirals Market, by Treatment Regimen
10.1. Combination Therapy
10.1.1. Dual Therapy
10.1.1.1. Ns3 4A Ns5A
10.1.1.2. Ns5A Ns5B
10.1.2. Triple Therapy
10.2. Monotherapy
11. Direct Acting Antivirals Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Direct Acting Antivirals Market, by End User
12.1. Hospitals
12.2. Retail Pharmacies
12.3. Specialty Clinics
13. Direct Acting Antivirals Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Direct Acting Antivirals Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Direct Acting Antivirals Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Direct Acting Antivirals Market
17. China Direct Acting Antivirals Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Amgen Inc.
18.7. AstraZeneca plc
18.8. Aurobindo Pharma Limited
18.9. Bayer AG
18.10. Biogen Inc.
18.11. Boehringer Ingelheim International GmbH
18.12. Bristol-Myers Squibb Company
18.13. Cipla Limited
18.14. Dr. Reddy’s Laboratories Ltd.
18.15. Eli Lilly and Company
18.16. Gilead Sciences, Inc.
18.17. GlaxoSmithKline plc
18.18. Hetero Labs Limited
18.19. Johnson & Johnson
18.20. Laurus Labs Limited
18.21. Lupin Limited
18.22. Merck & Co., Inc.
18.23. Natco Pharma Limited
18.24. Novartis AG
18.25. Pfizer Inc.
18.26. Pharco Pharmaceuticals
18.27. Regeneron Pharmaceuticals, Inc.
18.28. Roche Holding AG
18.29. Sanofi S.A.
18.30. Strides Pharma Science Limited
18.31. Takeda Pharmaceutical Company Limited
18.32. Teva Pharmaceutical Industries Ltd.
18.33. Vertex Pharmaceuticals Incorporated
18.34. Viatris Inc.
18.35. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 151. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 152. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 153. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 155. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 156. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 157. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 158. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 159. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 176. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 177. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 178. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 179. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 181. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 182. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 183. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 184. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 185. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 201. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 203. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 204. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 206. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 208. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 209. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 210. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 211. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 212. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 216. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 218. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 219. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 221. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 222. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 223. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 224. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 225. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 242. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 243. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 244. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 245. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 246. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 247. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 248. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 249. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 250. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 251. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 254. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 255. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 256. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 257. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 258. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 260. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 261. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 262. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 263. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 264. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 265. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 267. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 268. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 269. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 270. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 271. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 272. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 273. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 274. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 275. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 276. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 277. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 278. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 293. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 294. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 295. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 296. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
TABLE 297. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 298. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 299. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
TABLE 300. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
TABLE 301. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 302. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 303. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
TABLE 304. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 305. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Direct Acting Antivirals market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Laurus Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Pharco Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Strides Pharma Science Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages180
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 52.37 Billion
Forecasted Market Value ( USD ) by 2032 $ 84.56 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032 - Product Image

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Direct-acting Antiviral Drug Market - Global Forecast 2026-2032 - Product Image

Direct-acting Antiviral Drug Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Antiviral Combination Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antiviral Combination Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Antivirals Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antivirals Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.